NDA 220185 is the FDA application for JIDEYTRO (zidesamtinib). The FDA's Orange Book lists the applicant of record as NUVALENT INC and the first approval on it as Jul 22, 2026. Code name used in development: NVL-520. Owner today: GSK plc (LSE/NYSE: GSK).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220185 · Orange Book NDA 220185
| Brand name (FDA) | JIDEYTRO Orange Book trade name: JIDEYTRO |
|---|---|
| Active ingredient (FDA) | ZIDESAMTINIB |
| Code name | NVL-520 Source: GSK press release, Jun 9, 2026 “Zidesamtinib (NVL-520) and neladalkib (NVL-655) are two late-stage, potential best-in-class,” |
| FDA applicant of record | NUVALENT INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | GSK plc (GSK) Source: GSK press release, Jul 22, 2026 “GSK plc (LSE/NYSE: GSK)” … “part of the portfolio from the recently completed acquisition of Nuvalent, Inc.” |
| Earlier / partner | Nuvalent, Inc. (ticker at the time: NUVL): acquired by the current owner, Jul 15, 2026 Source: GSK 6-K, Jul 15, 2026 “GSK plc (LSE/NYSE: GSK) today announced completion of its acquisition of Nuvalent, Inc.” … “Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | JIDEYTRO | TABLET;ORAL | 25MG | Jul 22, 2026 |
| 002 | JIDEYTRO | TABLET;ORAL | 100MG | Jul 22, 2026 |
Drug page: /drug/zidesamtinib
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.